Literature DB >> 30825223

Dealing with an insufficient future liver remnant: Portal vein embolization and two-stage hepatectomy.

Yoshikuni Kawaguchi1, Heather A Lillemoe1, Jean-Nicolas Vauthey1.   

Abstract

Colorectal liver metastases (CLM) are not always resectable at the time of diagnosis. An insufficient future liver remnant is a factor excluding patients from curative intent resection. To deal with this issue, two-stage hepatectomy was introduced approximately 20 years ago. It is a sequential treatment strategy for bilateral CLM, which consists of preoperative chemotherapy, portal vein embolization, and planned first and second liver resections. This study reviews current evidence supporting use of two-stage hepatectomy.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  colorectal liver metastasis; future liver remnant; portal vein embolization; two-stage hepatectomy

Mesh：

Substances：

Year:  2019        PMID： 30825223      PMCID： PMC6422720          DOI： 10.1002/jso.25430

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  91 in total

1.  Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations.

Authors:  J N Vauthey; A Chaoui; K A Do; M M Bilimoria; M J Fenstermacher; C Charnsangavej; M Hicks; G Alsfasser; G Lauwers; I F Hawkins; J Caridi
Journal:  Surgery       Date:  2000-05       Impact factor: 3.982

2.  One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases.

Authors:  Daniel Jaeck; Philippe Bachellier; Hiroshi Nakano; Elie Oussoultzoglou; Jean-Christophe Weber; Philippe Wolf; Michel Greget
Journal:  Am J Surg       Date:  2003-03       Impact factor: 2.565

3.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

Review 4.  [Extended liver resection for hilar cholangiocarcinoma].

Authors:  M Nagino; J Kamiya; K Uesaka; T Sano; N Yuasa; K Oda; M Kanai; H Yamamoto; N Hayakawa; Y Nimura
Journal:  Nihon Geka Gakkai Zasshi       Date:  2000-05

5.  New frontiers in liver surgery. Two-stage liver surgery for the management of advanced metastatic liver disease.

Authors:  N J Lygidakis; L Vlachos; S Raptis; G Rassidakis; C Balaskas; G Sgourakis; D Mourikis; D Kehagias; C Kittas
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug

6.  Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver.

Authors:  D Azoulay; D Castaing; J Krissat; A Smail; G M Hargreaves; A Lemoine; J F Emile; H Bismuth
Journal:  Ann Surg       Date:  2000-11       Impact factor: 12.969

7.  Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors.

Authors:  R Adam; A Laurent; D Azoulay; D Castaing; H Bismuth
Journal:  Ann Surg       Date:  2000-12       Impact factor: 12.969

8.  Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume.

Authors:  K Shirabe; M Shimada; T Gion; H Hasegawa; K Takenaka; T Utsunomiya; K Sugimachi
Journal:  J Am Coll Surg       Date:  1999-03       Impact factor: 6.113

9.  Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection.

Authors:  Margo Shoup; Mithat Gonen; Michael D'Angelica; William R Jarnagin; Ronald P DeMatteo; Lawrence H Schwartz; Scott Tuorto; Leslie H Blumgart; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

10.  Portal vein embolization vs. portal vein ligation for induction of hypertrophy of the future liver remnant.

Authors:  Dieter C Broering; Christian Hillert; Gerrit Krupski; Lutz Fischer; Lars Mueller; Eike G Achilles; Jan Schulte am Esch; Xavier Rogiers
Journal:  J Gastrointest Surg       Date:  2002 Nov-Dec       Impact factor: 3.267
View more
  22 in total

Review 1.  Modern therapeutic approaches for the treatment of malignant liver tumours.

Authors:  Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-17       Impact factor: 46.802

Review 2.  Gene mutation and surgical technique: Suggestion or more?

Authors:  Yoshikuni Kawaguchi; Heather A Lillemoe; Jean-Nicolas Vauthey
Journal:  Surg Oncol       Date:  2019-07-18       Impact factor: 3.279

Review 3.  Colorectal liver metastases: state-of-the-art management and surgical approaches.

Authors:  Timothy E Newhook; Jean-Nicolas Vauthey
Journal:  Langenbecks Arch Surg       Date:  2022-04-09       Impact factor: 2.895

4.  Innovation and Future Perspectives in the Treatment of Colorectal Liver Metastases.

Authors:  Jean-Nicolas Vauthey; Yoshikuni Kawaguchi
Journal:  J Gastrointest Surg       Date:  2019-12-03       Impact factor: 3.452

Review 5.  Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments.

Authors:  Yoshikuni Kawaguchi; Mario De Bellis; Elena Panettieri; Gregor Duwe; Jean-Nicolas Vauthey
Journal:  Surg Oncol Clin N Am       Date:  2020-10-27       Impact factor: 3.495

6.  Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status.

Authors:  Y Kawaguchi; S Kopetz; H S Tran Cao; E Panettieri; M De Bellis; Y Nishioka; H Hwang; X Wang; C-W D Tzeng; Y S Chun; T A Aloia; K Hasegawa; A Guglielmi; F Giuliante; J-N Vauthey
Journal:  Br J Surg       Date:  2021-08-19       Impact factor: 6.939

7.  Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer.

Authors:  Yoshikuni Kawaguchi; Scott Kopetz; Elena Panettieri; Hyunsoo Hwang; Xuemei Wang; Hop S Tran Cao; Ching-Wei D Tzeng; Yun Shin Chun; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2021-09-10       Impact factor: 3.452

Review 8.  Surgical approach to synchronous colorectal liver metastases: staged, combined, or reverse strategy.

Authors:  Heather A Lillemoe; Jean-Nicolas Vauthey
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

9.  Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases.

Authors:  Yoshikuni Kawaguchi; Timothy E Newhook; Hop S Tran Cao; Ching-Wei D Tzeng; Yun Shin Chun; Thomas A Aloia; Arvind Dasari; Scott Kopetz; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2020-11-17       Impact factor: 3.452

10.  Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.

Authors:  Yoshikuni Kawaguchi; Scott Kopetz; Lawrence Kwong; Lianchun Xiao; Jeffrey S Morris; Hop S Tran Cao; Ching-Wei D Tzeng; Yun Shin Chun; Jeffrey E Lee; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2021-06-07       Impact factor: 6.532
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.